Research graph
References from Impact of Time and Temperature on Glycation, Oxidation, and Functional Stability of Trastuzumab Deruxtecan (ENHERTU®) in Dextrose Infusion Bags. Local targets link to admitted publications; unresolved targets remain external evidence.
Guidelines for the practical stability studies of anticancer drugs: a European consensus conference
10.1016/j.pharma.2011.07.002 · 2011 · External reference
Strategies and challenges for the next generation of antibody-drug conjugates
10.1038/nrd.2016.268 · 2017 · External reference
Unresolved reference
2000 · External reference
Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors
10.1016/j.molimm.2009.02.002 · 2009 · External reference
Oxygen dependency of one-electron reactions generating ascorbate radicals and hydrogen peroxide from ascorbic acid
10.1016/j.foodchem.2015.07.141 · 2016 · External reference
Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality
10.1002/jps.21530 · 2009 · External reference
Fast analysis of recombinant monoclonal antibodies using IdeS proteolytic digestion and electrospray mass spectrometry
10.1016/j.ab.2011.04.030 · 2011 · External reference
Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation
10.1023/a:1025771421906 · 2003 · External reference
Photo-oxidation of proteins and its role in cataractogenesis
10.1016/s1011-1344(01)00208-1 · 2001 · External reference
A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab Deruxtecan
10.31083/j.fbl2710290 · 2022 · External reference
Hospital in-use evaluation of the physical, chemical and affinity stability of the antibody-drug conjugate trastuzumab deruxtecan (Enhertu®)
10.1016/j.ejps.2026.107536 · 2026 · External reference
Theory and practice of size exclusion chromatography for the analysis of protein aggregates
10.1016/j.jpba.2014.04.011 · 2014 · External reference
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose
10.1073/pnas.1108455108 · 2011 · External reference
Glycation during storage and administration of monoclonal antibody formulations
10.1016/j.ejpb.2008.04.021 · 2008 · External reference
Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes
10.4161/mabs.27876 · 2014 · External reference
Detection, identification, and quantification of oxidative protein modifications
10.1074/jbc.rev119.006217 · 2019 · External reference
Size-Exclusion Chromatography for the Analysis of Protein Biotherapeutics and their Aggregates
10.1080/10826076.2012.743724 · 2012 · External reference
Post-translational modifications differentially affect IgG1 conformation and receptor binding
10.1074/mcp.m900540-mcp200 · 2010 · External reference
Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends
10.1016/j.drudis.2016.04.004 · 2016 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Glycosylation of recombinant antibody therapeutics
10.1021/bp040016j · 2005 · External reference
Methionine, tryptophan, and histidine oxidation in a model protein, PTH: mechanisms and stabilization
10.1002/jps.21746 · 2009 · External reference
Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release
10.1002/jps.23018 · 2012 · External reference
Evaluating the Potential of Cyclodextrins in Reducing Aggregation of Antibody–Drug Conjugates with Different Payloads
10.1016/j.xphs.2024.04.024 · 2024 · External reference
Antibody-Drug Conjugates: A Comprehensive Review
10.1158/1541-7786.mcr-19-0582 · 2020 · External reference
Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization
10.1002/bit.260480511 · 1995 · External reference
Analysis of reduced monoclonal antibodies using size exclusion chromatography coupled with mass spectrometry
10.1016/j.jasms.2009.08.015 · 2009 · External reference
Insights into Photo Degradation and Stabilization Strategies of Antibody-Drug Conjugates with Camptothecin Payloads
10.3390/pharmaceutics17111397 · 2025 · External reference
Effect of high shear on proteins
10.1002/(sici)1097-0290(19960820)51:4<458::aid-bit9>3.0.co;2-h · 1996 · External reference
Protein aggregation: pathways, induction factors and analysis
10.1002/jps.21566 · 2009 · External reference
The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
10.1248/cpb.c18-00744 · 2019 · External reference
Forced degradation of recombinant monoclonal antibodies: A practical guide
10.1080/19420862.2017.1368602 · 2017 · External reference
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
10.1158/1078-0432.ccr-15-2822 · 2016 · External reference
Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice
10.1080/00498254.2020.1755909 · 2020 · External reference
In-depth Characterization of Photo-Stressed Antibody-Drug Conjugates by Mass Spectrometry
10.1208/s12248-026-01247-6 · 2026 · External reference
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
10.1002/cmdc.201900497 · 2020 · External reference
Therapeutic protein aggregation: mechanisms, design, and control
10.1016/j.tibtech.2014.05.005 · 2014 · External reference
Protein aggregation and its impact on product quality
10.1016/j.copbio.2014.08.001 · 2014 · External reference
Non-native protein aggregation kinetics
10.1002/bit.21627 · 2007 · External reference
Molecular clocks
10.1073/pnas.98.3.944 · 2001 · External reference
Effects of protein aggregates: An immunologic perspective
10.1208/aapsj080359 · 2006 · External reference
Mechanistic insight into the oxidative degradation of monoclonal antibodies: relevance to developability and the design of stable pharmaceutical formulations
10.1042/bst20250134 · 2026 · External reference
Photo-Degradation of Therapeutic Proteins: Mechanistic Aspects
10.1007/s11095-020-2763-8 · 2020 · External reference
High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R
10.1074/jbc.m009483200 · 2001 · External reference
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
10.1074/jbc.m210665200 · 2003 · External reference
Dynamic light scattering: a practical guide and applications in biomedical sciences
10.1007/s12551-016-0218-6 · 2016 · External reference
Development and use of specific ELISA methods for quantifying the biological activity of bevacizumab, cetuximab and trastuzumab in stability studies
10.1016/j.jchromb.2016.05.045 · 2016 · External reference
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
10.1038/s41467-025-58266-8 · 2025 · External reference
Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods
10.2174/138920108786786402 · 2008 · External reference
Analytical methods for physicochemical characterization of antibody drug conjugates
10.4161/mabs.3.2.14960 · 2011 · External reference
Protein aggregation and its inhibition in biopharmaceutics
10.1016/j.ijpharm.2004.11.014 · 2005 · External reference
Protein aggregation – Mechanisms, detection, and control
10.1016/j.ijpharm.2018.08.043 · 2018 · External reference
Protein aggregation - Mechanisms, detection, and control
10.1016/j.ijpharm.2018.08.043 · 2018 · External reference
Antibody structure, instability, and formulation
10.1002/jps.20727 · 2007 · External reference
IgG Fc engineering to modulate antibody effector functions
10.1007/s13238-017-0473-8 · 2018 · External reference
Protein G, Protein A and Protein-A-Derived Peptides Inhibit the Agitation Induced Aggregation of IgG
10.1021/mp200548x · 2012 · External reference
